Tocilizumab is associated with reduction in inflammation and improvement in P/F ratio in critically sick COVID19 patients

Muhammad Asim Rana, Mubashar Hashmi, Muhammad Muneeb Ullah Saif, Muhammad Faisal Munir, Ahad Qayyum, Rizwan Pervaiz, Muhammad Mansoor Hafeez
doi: https://doi.org/10.1101/2020.10.20.20210195

Article Information

doi 
https://doi.org/10.1101/2020.10.20.20210195
History 
  • October 21, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Muhammad Asim Rana1,*,
  2. Mubashar Hashmi1,
  3. Muhammad Muneeb Ullah Saif2,
  4. Muhammad Faisal Munir2,
  5. Ahad Qayyum3,
  6. Rizwan Pervaiz1 and
  7. Muhammad Mansoor Hafeez4
  1. 1Department of Critical Care, Division of Medicine, Bahria International Hospital, Lahore, Pakistan
  2. 2Department of Critical Care Nursing, Division of Medicine, Bahria International Hospital, Lahore, Pakistan
  3. 3Department of Nephrology, Division of Medicine, Bahria International Hospital, Lahore, Pakistan
  4. 4Institute of molecular biology and biotechnology, University of Lahore
  1. ↵*Corresponding author; email: drasimrana{at}yahoo.com
Back to top
Posted October 21, 2020.
Download PDF
Data/Code
Email
Tocilizumab is associated with reduction in inflammation and improvement in P/F ratio in critically sick COVID19 patients
Muhammad Asim Rana, Mubashar Hashmi, Muhammad Muneeb Ullah Saif, Muhammad Faisal Munir, Ahad Qayyum, Rizwan Pervaiz, Muhammad Mansoor Hafeez
medRxiv 2020.10.20.20210195; doi: https://doi.org/10.1101/2020.10.20.20210195
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area